Launching Disruptive Products and Building Your Commercialization Team

For our October 31st webinar, Galen Data is honored to be joined by veteran MedTech innovator, board member, advisor, and venture capitalist, Ken Nelson of the MedTech Advantage Fund. Ken will share his career experiences spanning from advising prototype-stage companies, to helping raise major venture rounds, to taking companies through product launch. He will describe the methods and thought processes he's seen succeed in navigating the current funding environment and in building your commercial team as you go to market. This webinar will offer insights for MedTech companies at any stage and provide critical insights on how you can prepare for the “commercialization chasm”. We encourage you to join us for the conversation and Q&A with Ken, who possesses a rare depth of full-lifecycle expertise.   

Key Takeaways: 

• Key considerations for creating an IPO-driven mindset 

• A high-level roadmap for avoiding commercialization failure 

• How to adapt in a constrained funding environment • Stories of how connectivity and the EHR created opportunities  

About Ken Nelson: Ken Nelson currently serves as partner in the Medtech Advantage Fund, which has an exclusive partnership with Medtech Innovator, the largest MedTech and Digital Health startup accelerator globally.  In addition, he serves as Chairman of the Board for CardiaCare, and is an active board member for HeartX, HeartBeam (NASDAQ:  BEAT), and a handful of other disruptive cardiac Digital Health and MedTech startups. Overall,  he is a 20 year digital health, medical device, and remote patient monitoring executive and innovator with successful senior leadership experience ranging from a Fortune 500 company (Boston Scientific) to a #1 market share leading medium sized company (Biotelemetry, acquisition by Philips for $2.8 Billion announced in December '20) to 3 start-ups, 1 of which eventually led to an extremely successful IPO (iRhythm) and another which was just acquired by HillRom/ Baxter (Bardy Diagnostics) in August 2021 for $400M+ after milestone payments.